Compare Payoneer Global Inc (PAYO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Payoneer Global Inc vs Recursion Pharmaceuticals Inc — how do they compare? Payoneer Global Inc trades at $7.11 (market cap $2.42B), while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B). The key difference: Payoneer Global Inc is the larger of the two by market cap, and Payoneer Global Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| PAYO | RXRX | |
|---|---|---|
Market Cap | $2.42B | $1.86B |
Sector | Technology | Health |
52-Week High | $7.18 | $6.79 |
52-Week Low | $4.27 | $2.84 |
Enterprise Value | $2.16B | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Payoneer Global (PAYO) trades at $7.13, down 0.56% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported Q2 2026 earnings of $0.02 per share, missing estimates, but revenue grew 10% year-over-year excluding interest. A pending acquisition by Nuvei for $7.40 per share announced in June 2026 is a key catalyst, though legal investigations question the deal's fairness.
The outlook hinges on the acquisition closing, offering a slight premium to current price, but execution risks and earnings volatility pose concerns. Analysts maintain a 60% buy rating, seeing value in cross-border payment growth, yet margin pressures and integration challenges post-acquisition are key investor risks.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
